EP Patent

EP4035664A2 — Treating cancer using selective estrogen receptor modulators

Assigned to Duke University · Expires 2022-08-03 · 4y expired

What this patent protects

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by a…

USPTO Abstract

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Drugs covered by this patent

Patent Metadata

Patent number
EP4035664A2
Jurisdiction
EP
Classification
—
Expires
2022-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Duke University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.